Patents by Inventor Albertus D.M.E. Osterhaus

Albertus D.M.E. Osterhaus has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11162148
    Abstract: The invention relates to the field of virology. The invention provides an isolated essentially mammalian negative-sense single-stranded RNA virus (MPV) within the subfamily Pneumovirinae of the family Paramyxoviridae and identifiable as phylogenetically corresponding to the genus Metapneumovirus and components thereof.
    Type: Grant
    Filed: December 30, 2019
    Date of Patent: November 2, 2021
    Assignee: Erasmus University Medical Center Rotterdam
    Inventors: Jan Cornelius De Jong, Ronaldus Adrianus Maria Fouchier, Bernadetta Gerarda Van Den Hoogen, Albertus D. M. E. Osterhaus, Jan Groen
  • Patent number: 10736958
    Abstract: The present invention relates to a composition comprising at least one ISCOM complex and at least one ectodomain from at least one hemagglutinin (HA) domain and at least one ectodomain from at least one neuraminidase (NA) domain from one or more influenza virus, wherein the extodomains represent ectodomains isolated from the influenza virus. The invention also regards a kit. The composition may be used as an immune stimulating medicine, immune modulating pharmaceutical or a vaccine e.g. against influenza for vertebrates, e.g. birds and mammals.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: August 11, 2020
    Assignee: Novavax AB
    Inventors: Albertus D. M. E. Osterhaus, Bror Morein, Karin Lovgren Bengtsson
  • Publication number: 20200140964
    Abstract: The invention relates to the field of virology. The invention provides an isolated essentially mammalian negative-sense single-stranded RNA virus (MPV) within the subfamily Pneumovirinae of the family Paramyxoviridae and identifiable as phylogenetically corresponding to the genus Metapneumovirus and components thereof.
    Type: Application
    Filed: December 30, 2019
    Publication date: May 7, 2020
    Inventors: Jan Cornelius DE JONG, Ronaldus Adrianus Maria FOUCHIER, Bernadetta Gerarda VAN DEN HOOGEN, Albertus D.M.E. OSTERHAUS, Jan GROEN
  • Publication number: 20190388534
    Abstract: The present invention relates to a composition comprising at least one ISCOM complex and at least one ectodomain from at least one hemagglutinin (HA) domain and at least one ectodomain from at least one neuraminidase (NA) domain from one or lore influenza virus, wherein the extodomains represent ectodomains isolated from the influenza virus. The invention also regards a kit. The composition may be used as an immune stimulating medicine, immune modulating pharmaceutical or a vaccine e.g. against influenza for vertebrates, e.g. birds and mammals.
    Type: Application
    Filed: January 29, 2019
    Publication date: December 26, 2019
    Inventors: Albertus D.M.E. OSTERHAUS, Bror MOREIN, Karin LOVGREN BENGTSSON
  • Patent number: 10485863
    Abstract: The present invention relates to a composition comprising at least one ISCOM complex and at least one ectodomain from at least one hemagglutinin (HA) domain and at least one ectodomain from at least one neuraminidase (NA) domain from one or more influenza virus, wherein the extodomains represent ectodomains isolated from the influenza virus. The invention also regards a kit. The composition may be used as an immune stimulating medicine, immune modulating pharmaceutical or a vaccine e.g. against influenza for vertebrates, e.g. birds and mammals.
    Type: Grant
    Filed: July 25, 2011
    Date of Patent: November 26, 2019
    Assignees: Novavax AB, Erasmus University Rotterdam Medical Center
    Inventors: Albertus D. M. E. Osterhaus, Bror Morein, Karin Lövgren Bengtsson
  • Patent number: 9376726
    Abstract: The present invention provides an isolated mammalian negative strand RNA virus, metapneumovirus (MPV), within the sub-family Pneumoviridae, of the family Paramyxoviridae. The invention also provides isolated mammalian negative strand RNA viruses identifiable as phylogenetically corresponding or relating to the genus Metapneumovirus and components thereof. In particular the invention provides a mammalian MPV, subgroups and variants thereof. The invention relates to genomic nucleotide sequences of different isolates of mammalian metapneumoviruses, in particular human metapneumoviruses. The invention relates to the use of the sequence information of different isolates of mammalian metapneumoviruses for diagnostic and therapeutic methods. The present invention relates to nucleotide sequences encoding the genome of a metapneumovirus or a portion thereof, including both mammalian and avian metapneumovirus. The invention further encompasses chimeric or recombinant viruses encoded by said nucleotide sequences.
    Type: Grant
    Filed: May 5, 2014
    Date of Patent: June 28, 2016
    Assignee: Erasmus University Medical Center Rotterdam
    Inventors: Ronaldus Adrianus Maria Fouchier, Bernadetta Gerarda Van Den Hoogen, Albertus D M E Osterhaus, Aurelia Haller, Roderick Tang
  • Patent number: 9334543
    Abstract: The invention relates to the field of virology. The invention provides an isolated essentially mammalian negative-sense single-stranded RNA virus (MPV) within the subfamily Pneumovirinae of the family Paramyxoviridae and identifiable as phylogenetically corresponding to the genus Metapneumovirus and components thereof.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: May 10, 2016
    Assignee: Erasmus University Medical Center Rotterdam
    Inventors: Jan Cornelius De Jong, Ronaldus Adrianus Maria Fouchier, Bernadetta Gerarda Van Den Hoogen, Albertus D M E Osterhaus, Jan Groen
  • Publication number: 20150093746
    Abstract: The invention relates to the field of virology. The invention provides an isolated essentially mammalian negative-sense single-stranded RNA virus (MPV) within the subfamily Pneumovirinae of the family Paramyxoviridae and identifiable as phylogenetically corresponding to the genus Metapneumovirus and components thereof.
    Type: Application
    Filed: November 25, 2014
    Publication date: April 2, 2015
    Inventors: Jan Cornelius De Jong, Ronaldus Adrianus Maria Fouchier, Bernadetta Gerarda Van Den Hoogen, Albertus D M E Osterhaus, Jan Groen
  • Publication number: 20140295409
    Abstract: The present invention provides an isolated mammalian negative strand RNA virus, metapneumovirus (MPV), within the sub-family Pneumoviridae, of the family Paramyxoviridae. The invention also provides isolated mammalian negative strand RNA viruses identifiable as phylogenetically corresponding or relating to the genus Metapneumovirus and components thereof. In particular the invention provides a mammalian MPV, subgroups and variants thereof. The invention relates to genomic nucleotide sequences of different isolates of mammalian metapneumoviruses, in particular human metapneumoviruses. The invention relates to the use of the sequence information of different isolates of mammalian metapneumoviruses for diagnostic and therapeutic methods. The present invention relates to nucleotide sequences encoding the genome of a metapneumovirus or a portion thereof, including both mammalian and avian metapneumovirus. The invention further encompasses chimeric or recombinant viruses encoded by said nucleotide sequences.
    Type: Application
    Filed: May 5, 2014
    Publication date: October 2, 2014
    Inventors: Ronaldus Adrianus Maria Fouchier, Bernadetta Gerarda Van Den Hoogen, Albertus D M E Osterhaus, Aurelia Haller, Roderick Tang
  • Patent number: 6319666
    Abstract: The presence of cytotoxic T-cells to the Rev and/or Tat protein in samples from a subject infected with immunodeficiency virus, particularly HIV in humans, is an indication of a stable disease condition and a favorable prognosis of lack of progression to disease. Immunogenic compositions containing at least one cytotoxic T-cell epitope of the Rev and/or Tat protein of an immunodeficiency virus, particularly HIV, or a vector encoding the T-cell epitope, may be used to prevent infection by disease caused by the immunodeficiency virus, by stimulating, in the host, a specific cytotoxic T-cell response specific for the respective Rev and/or Tat proteins.
    Type: Grant
    Filed: June 17, 1999
    Date of Patent: November 20, 2001
    Assignee: Erasmus Universiteit Rotterdam
    Inventors: Carel A. Van Baalen, Albertus D.M.E. Osterhaus
  • Patent number: 6024965
    Abstract: The presence of cytotoxic T-cells to the Rev and/or Tat protein in samples from a subject infected with immunodeficiency virus, particularly HIV in humans, is an indication of a stable disease condition and a favourable prognosis of lack of progression to disease. Immunogenic compositions containing at least one cytotoxic T-cell epitope of the Rev and/or Tat protein of an immunodeficiency virus, particularly HIV, or a vector encoding the T-cell epitope, may be used to prevent infection by disease caused by the immunodeficiency virus, by stimulating, in the host, a specific cytotoxic T-cell response specific for the respective Rev and/or Tat proteins.
    Type: Grant
    Filed: October 18, 1996
    Date of Patent: February 15, 2000
    Assignee: Erasums University Rotterdam
    Inventors: Carel A. van Baalen, Albertus D. M. E. Osterhaus
  • Patent number: 5942401
    Abstract: The presence of cytotoxic T-cells to the Rev and/or Tat protein in samples from a subject infected with immunodeficiency virus, particularly HIV in humans, is an indication of a stable disease condition and a favourable prognosis of lack of progression to disease. Immunogenic compositions containing at least one cytotoxic T-cell epitope of the Rev and/or Tat protein of an immunodeficiency virus, particularly HIV, or a vector encoding the T-cell epitope, may be used to prevent infection by disease caused by the immunodeficiency virus, by stimulating, in the host, a specific cytotoxic T-cell response specific for the respective Rev and/or Tat proteins.
    Type: Grant
    Filed: December 22, 1997
    Date of Patent: August 24, 1999
    Assignee: Connaught Laboratories Limited
    Inventors: Carel A. van Baalen, Albertus D. M. E. Osterhaus
  • Patent number: 4293653
    Abstract: A process for propagating feline infectious peritonitis (FIP) virus in which suckling rodents are intracerebrally inoculated with infectious cat material, containing the feline infectious peritonitis virus, the virus is replicated in the brain of the infected suckling rodent and the infected brain material is then harvested from the infected rodents.
    Type: Grant
    Filed: April 12, 1979
    Date of Patent: October 6, 1981
    Inventors: Marian C. Horzinek, Albertus D. M. E. Osterhaus